​​​
  1. Dr Reddy’s launches generic hepatitis C drug in India

Dr Reddy’s launches generic hepatitis C drug in India

Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country.

By: | Published: May 15, 2017 5:16 PM
The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy’s Laboratories said in a statement.

Dr Reddy’s Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country. The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy’s Laboratories said in a statement.

Dr Reddy’s product is a generic version of Gilead’s brand Epclusa. “Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus,” the company said.

Shares of the company ended 3.54 per cent up at Rs 2,676.15 on BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

  1. No Comments.

Go to Top